These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 30361253)

  • 1. Compassionate use of delamanid in combination with bedaquiline for the treatment of multidrug-resistant tuberculosis.
    Hafkin J; Hittel N; Martin A; Gupta R
    Eur Respir J; 2019 Jan; 53(1):. PubMed ID: 30361253
    [No Abstract]   [Full Text] [Related]  

  • 2. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
    Ferlazzo G; Mohr E; Laxmeshwar C; Hewison C; Hughes J; Jonckheere S; Khachatryan N; De Avezedo V; Egazaryan L; Shroufi A; Kalon S; Cox H; Furin J; Isaakidis P
    Lancet Infect Dis; 2018 May; 18(5):536-544. PubMed ID: 29452942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review.
    Pontali E; Sotgiu G; Tiberi S; Tadolini M; Visca D; D'Ambrosio L; Centis R; Spanevello A; Migliori GB
    Eur Respir J; 2018 Jul; 52(1):. PubMed ID: 29903862
    [No Abstract]   [Full Text] [Related]  

  • 4. Bedaquiline and delamanid in combination for treatment of drug-resistant tuberculosis.
    Mohr E; Ferlazzo G; Hewison C; De Azevedo V; Isaakidis P
    Lancet Infect Dis; 2019 May; 19(5):470. PubMed ID: 31034392
    [No Abstract]   [Full Text] [Related]  

  • 5. Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis.
    Bloemberg GV; Keller PM; Stucki D; Trauner A; Borrell S; Latshang T; Coscolla M; Rothe T; Hömke R; Ritter C; Feldmann J; Schulthess B; Gagneux S; Böttger EC
    N Engl J Med; 2015 Nov; 373(20):1986-8. PubMed ID: 26559594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bedaquiline or delamanid for rifampin-resistant tuberculosis?
    Lessem E; Cox V; Furin J
    Lancet Respir Med; 2017 Oct; 5(10):772-774. PubMed ID: 28887015
    [No Abstract]   [Full Text] [Related]  

  • 7. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.
    Dooley KE; Rosenkranz SL; Conradie F; Moran L; Hafner R; von Groote-Bidlingmaier F; Lama JR; Shenje J; De Los Rios J; Comins K; Morganroth J; Diacon AH; Cramer YS; Donahue K; Maartens G;
    Lancet Infect Dis; 2021 Jul; 21(7):975-983. PubMed ID: 33587897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Failure and Acquired Bedaquiline and Delamanid Resistance in Treatment of Drug-Resistant TB.
    Millard J; Rimmer S; Nimmo C; O'Donnell M
    Emerg Infect Dis; 2023 May; 29(5):1081-1084. PubMed ID: 37081529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis.
    Cox V; Brigden G; Crespo RH; Lessem E; Lynch S; Rich ML; Waning B; Furin J
    Int J Tuberc Lung Dis; 2018 Apr; 22(4):407-412. PubMed ID: 29562988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.
    Polsfuss S; Hofmann-Thiel S; Merker M; Krieger D; Niemann S; Rüssmann H; Schönfeld N; Hoffmann H; Kranzer K
    Clin Infect Dis; 2019 Sep; 69(7):1229-1231. PubMed ID: 30933266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study.
    Franke MF; Khan P; Hewison C; Khan U; Huerga H; Seung KJ; Rich ML; Zarli K; Samieva N; Oyewusi L; Nair P; Mudassar M; Melikyan N; Lenggogeni P; Lecca L; Kumsa A; Khan M; Islam S; Hussein K; Docteur W; Chumburidze N; Berikova E; Atshemyan H; Atwood S; Alam M; Ahmed S; Bastard M; Mitnick CD
    Am J Respir Crit Care Med; 2021 Jan; 203(1):111-119. PubMed ID: 32706644
    [No Abstract]   [Full Text] [Related]  

  • 12. Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.
    Maryandyshev A; Pontali E; Tiberi S; Akkerman O; Ganatra S; Sadutshang TD; Alffenaar JW; Amale R; Mullerpattan J; Topgyal S; Udwadia ZF; Centis R; D'Ambrosio L; Sotgiu G; Migliori GB
    Emerg Infect Dis; 2017 Oct; 23(10):1718-21. PubMed ID: 28758888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
    Wirth D; Dass R; Hettle R
    BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.
    Migliori GB; Pontali E; Sotgiu G; Centis R; D'Ambrosio L; Tiberi S; Tadolini M; Esposito S
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28178199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Access to new medications for the treatment of drug-resistant tuberculosis: patient, provider and community perspectives.
    Lessem E; Cox H; Daniels C; Furin J; McKenna L; Mitnick CD; Mosidi T; Reed C; Seaworth B; Stillo J; Tisile P; von Delft D
    Int J Infect Dis; 2015 Mar; 32():56-60. PubMed ID: 25809757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidrug Resistant Tuberculosis With Simultaneously Acquired Drug Resistance to Bedaquiline and Delamanid.
    Yoshiyama T; Takaki A; Aono A; Mitarai S; Okumura M; Ohta K; Kato S
    Clin Infect Dis; 2021 Dec; 73(12):2329-2331. PubMed ID: 32730621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens.
    Khan U; Huerga H; Khan AJ; Mitnick CD; Hewison C; Varaine F; Bastard M; Rich M; Franke MF; Atwood S; Khan PY; Seung KJ
    BMC Infect Dis; 2019 Aug; 19(1):733. PubMed ID: 31429722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of drug resistantTB in patients with HIV co-infection.
    Pontali E; Sotgiu G; Centis R; D'Ambrosio L; Spanevello A; Migliori GB
    Expert Opin Pharmacother; 2015; 16(18):2737-50. PubMed ID: 26478945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Six-Month Response to Delamanid Treatment in MDR TB Patients.
    Hewison C; Ferlazzo G; Avaliani Z; Hayrapetyan A; Jonckheere S; Khaidarkhanova Z; Mohr E; Sinha A; Skrahina A; Vambe D; Vasilyeva I; Lachenal N; Varaine F
    Emerg Infect Dis; 2017 Oct; 23(10):1746-8. PubMed ID: 28767036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study.
    Bonnet M; Bastard M; du Cros P; Khamraev A; Kimenye K; Khurkhumal S; Hayrapetyan A; Themba D; Telnov A; Sanchez-Padilla E; Hewison C; Varaine F
    Int J Tuberc Lung Dis; 2016 Feb; 20(2):177-86. PubMed ID: 26792469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.